HHS region, † the state of Florida, and nationally, with and without Florida. This allows geographic variation in RSV activity to be described and accommodates the unusually early and sometimes long RSV season observed in Florida (3).
During July 2011-June 2012, a total of 522 laboratories reported at least 1 week of RSV testing by any detection method to NREVSS. CDC limited this analysis to 174 (33.3%) laboratories in 42 states that met the following criteria: 1) reported RSV antigen testing results for ≥30 weeks during the NREVSS season and 2) averaged ≥10 tests per week during the NREVSS season. Qualifying laboratories reported a total of 270,441 tests, of which 41,299 (15.3%) were positive.
Respiratory Syncytial Virus Activity -United States, July 2011-January 2013 * In NREVSS, the onset week in an area (national, regional, or state) is defined as the first of 2 consecutive weeks when the weekly mean of the percentages of specimens testing positive for RSV antigen in all reporting laboratories in the area is ≥10%. The offset is the last of 2 consecutive weeks when the mean percent positive drops below this threshold. The season duration is the onset week, the weeks between onset and offset, and the offset week. The peak is the week when the mean percentage of positive RSV antigen tests is the highest.
Nationally, RSV onset occurred the week ending November 19, 2011, and lasted 21 weeks, until the week ending April 7, 2012 (Table) . Nationally, RSV onset occurred the week ending October 27, 2012; however, when Florida is excluded from analysis, the national onset occurred 1 week later (week ending November 10, 2012) (Table) . Weekly updates of RSV national, regional, and state RSV trends are available from NREVSS at http://www.cdc.gov/ surveillance/nrevss. Additional information regarding Florida RSV trends is available from the Florida Department of Health at http://www.doh.state.fl.us/disease_ctrl/epi/rsv/rsv.htm.
What is already known on this topic?
In the United States, respiratory syncytial virus (RSV) begins circulating in the fall, peaks in the winter, and ends during spring. A network of U.S. laboratories reports results of specimens tested for RSV to the National Respiratory and Enteric Virus Surveillance System, which summarizes national, regional, and state-level RSV activity.
What is added by this report?
For the 2011-12 season, RSV circulation began nationally in mid-November and ended in early April. Circulation peaked at 26% of tests positive in late January. During the 2012-13 RSV season, onset occurred in all but one of the 10 U.S. Department of Health and Human Services regions by December 15, 2012. These patterns in national RSV circulation were similar to those observed previously. Onset, offset, and duration varied among the regions and Florida.
What are the implications for public health practice?
RSV surveillance alerts public health officials and clinicians to times when respiratory infections might be attributed to RSV and when patients at high risk for severe complications of infection might need RSV immunoprophylaxis. 
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Editorial Note
During July 2011-June 2012, national and regional RSV trends were similar to patterns previously reported for 2010-11. Florida's season onset occurred 5 weeks earlier than the previous season, and each HHS region differed in onset, offset, and duration. Florida's earlier onset has been well documented, as have differences in activity from year-to-year in the same geographic location (3). Social and demographic factors, population density, pollution, and climate each might influence RSV activity (3) (4) (5) (6) .
NREVSS surveillance data can be used to identify RSV activity and coordinate timing of RSV immunoprophylaxis with palivizumab. Palivizumab is a monoclonal antibody against RSV recommended by the American Academy of Pediatrics (AAP) to be administered to children at high risk for severe RSV disease (7) . AAP also provides guidelines for identifying infants and young children likely to benefit from immunoprophylaxis (e.g., certain infants with congenital heart disease or chronic lung disease, and those born prematurely) and for timing of RSV immunoprophylaxis by region (7) . NREVSS provides timely data on RSV activity at the national, regional, and state levels, which have been correlated with numbers of RSV-associated hospitalizations in select regions (8) . Consequently, health-care providers and public health officials use NREVSS data to guide diagnostic testing and to assess possible causes of regional respiratory infection outbreaks.
The findings in this report are subject to at least four limitations. First, reporting to NREVSS is voluntary and might be biased to more active reporters. Second, the percent positive detections reflect not only disease burden (i.e., number of cases per capita or severity of seasonal outbreaks) but also the volume of tests ordered. Third, although NREVSS data can be used to approximate regional RSV seasonal characteristics, they cannot be used to estimate RSV activity in every state or county because participation varies from year-to-year and between states. Finally, periods of low RSV activity might not be captured by the NREVSS onset and offset definitions. Despite these limitations, NREVSS provides useful guidance to physicians ordering diagnostic tests and planning to initiate immunoprophylaxis. 
